Found Review: What Its GLP-1 Program Documents—and What It Does Not Prove

Found’s public documentation answers several practical questions: it offers online clinical assessment, prescription options, app-based support and both insurance-linked and cash-pay plans. It does not answer a different question simply by describing those services: how well Found’s own program or compounded preparations perform. For someone comparing treatment providers, separating service documentation from clinical evidence is more useful than treating every reference to GLP-1 research as validation of the entire package.

This review examines Found’s consulted pages as of October 19, 2026, including medication descriptions, pricing terms and billing consent. The documentation is detailed enough to identify meaningful differences between plans, but not fully consistent about upfront payment, Medicare access or some branded-drug prices. Found is a documented GLP-1 provider, not merely an adjacent wellness business. That classification establishes what it offers—not independent verification of its clinical credentials, pharmacy testing claims or treatment outcomes.

At a glance

Documented treatment options: Found advertises branded GLP-1 medications, compounded injectable semaglutide and tirzepatide, and non-GLP-1 oral generic options.
Sources: [9] [5] [12] [10]
Compounded-drug status: Found acknowledges that compounded medications are not FDA approved or evaluated by FDA for safety or efficacy, and are not available in every state.
Sources: [10]
Billing interval: The terms describe recurring prices using four-week, 28-day cycles; the 12-month plan tables specify 48 weeks, not a calendar year.
Sources: [10]
Insurance visits cost extra: Insurance-based care requires synchronous video visits, including before each refill, with a visit copay typically around $30 in addition to the plan price.
Sources: [13]
Pharmacy verification limit: Found says its compounded semaglutide is externally tested for potency, purity and sterility, but the consulted documentation does not identify the testing laboratory or provide certificates of analysis.
Sources: [9]

Start with what Found’s documents can establish

Found describes itself as an online weight-loss program offering personalized care, with input from obesity medicine specialists in its design. It also says every Found clinician is board-certified and trained in metabolic medicine. Those are provider representations, not independently verified credentials in this review. The billing consent identifies affiliated medical entities, including Pippen groups in several states, illustrating that the platform and the clinical organizations involved are not necessarily interchangeable.

The program’s documented scope extends beyond prescribing. Its compounded plan lists a metabolic assessment, access to weight-care professionals, medication, one-to-one health coaching, lifestyle tools and a member community. The pricing page also advertises medical, lifestyle and behavioral guidance. These descriptions establish promised service components; they do not establish how often coaching occurs, how consistently members use it or whether the combined program produces a particular amount of weight loss.

This distinction matters when reading marketing alongside drug research. A medication trial can answer a defined question about a studied treatment without measuring Found’s enrollment process, coaching or pharmacy product. Our guide to what provider documents can prove explains that boundary. Here, the strongest documentary evidence concerns the existence and terms of services, while the consulted material does not establish independently measured outcomes for Found’s complete program.

Sources: [9] [14] [7] [10] [12]

The medication menu contains different evidence questions

Found advertises branded products including Ozempic, Wegovy, Zepbound and Mounjaro, alongside compounded preparations and oral non-GLP-1 generics. It explicitly distinguishes medications approved for obesity from drugs approved for other conditions that clinicians may prescribe off-label for weight loss. A reader therefore needs the actual proposed product and indication, not just confirmation that the program offers “GLP-1s.” FDA approval belongs to a specific product, not to Found as a platform.

Its compounded semaglutide page describes a once-weekly subcutaneous injection for adults who may benefit from weight loss. Its compounded tirzepatide page describes a once-weekly injectable option for adults with obesity or overweight, specifying a BMI of at least 25 plus at least one weight-related condition. These are Found’s stated criteria, not a universal eligibility rule or a promise that an applicant will receive a prescription.

Found also markets compounded injectable semaglutide through a “microdosing” program. That page states that compounded GLP-1s are not approved to treat a specific condition and prescriptions require clinical appropriateness after evaluation. The consulted documentation does not establish complete admission criteria or prices for that offering. Evidence for an approved product should not silently transfer to another preparation or regimen; formulation and route matter when deciding what research actually applies.

Sources: [9] [5] [7] [12] [6] [10] [3]

Clinical research does not certify the service

The central regulatory distinction is straightforward: compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality. That absence does not by itself demonstrate clinical inequivalence, nor does it validate a pharmacy or provider. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That recommendation should not be converted into a blanket legal conclusion about Found.

The major semaglutide and tirzepatide trials were not trials of Found, its compounded products, its microdosing program or its app. Their results cannot establish this provider’s effectiveness or predict an individual member’s outcome. The distinction between approved medicines and compounded preparations remains important even when ingredient names overlap. Nothing in the consulted clinical context supplies a head-to-head provider ranking or an independent performance evaluation of Found’s care model.

Clinical follow-up should also involve more than continued access to medication. NIDDK describes treatment selection as a discussion of benefits, side effects, other medicines, health history and costs, with ongoing attention to response and tolerance. Medication accompanies eating and activity changes rather than replacing them. These principles give readers a framework for evaluating the substance of Found’s promised support, without assuming that an advertised follow-up schedule proves the quality of every encounter.

Sources: [1] [3] [4] [2]

Assessment, refills and support depend on the payment route

For compounded semaglutide, Found describes a short health assessment followed by a clinician’s review of health history, prior attempts and practical circumstances. Prescribing depends on appropriateness. The homepage says medication ships home after evaluation and eligibility, and claims most members can start within a week. That is a broad treatment-start statement—not a guaranteed clinical-review deadline, dispatch date or delivery commitment. The documentation does not separate those stages into reliable individual timelines.

The payment route changes the encounter format. With insurance, Found requires synchronous video visits, including before every refill; the visit is billed to insurance, typically with an approximately $30 copay beyond the plan charge. Cash-pay care is text-based and asynchronous in most cases, with no separate visit copay. This is a substantive service difference, not simply two prices for an otherwise identical sequence of appointments.

Found’s tirzepatide page promises monthly care-team follow-up to review response and address challenges. Its semaglutide page describes guidance on injection, storage and disposal, plus messaging between visits. Messaging access does not promise an immediate response. Likewise, 24/7 access to Aimee means access to an AI health companion, not continuous human clinical coverage. The value of clinical follow-up depends on what is reviewed and how concerns are handled, not availability language alone.

Sources: [9] [5] [7] [13] [12]

Pharmacy assurances need identifiable supporting records

Found says it partners exclusively with 503A pharmacies for compounded medication and describes prescription-specific preparation by licensed pharmacists under sterile-preparation standards. It also says compounded semaglutide receives third-party potency, purity and sterility testing before shipment. These are meaningful claims to investigate, but the consulted documentation does not name the compounding pharmacies or external laboratory, or provide certificates of analysis. Stating the testing claim is not the same as independently checking its results.

Geography and delivery remain less settled. Found warns that compounded medications are unavailable in some states, but the consulted pages do not establish a definitive medication-by-medication availability list. Nor do they establish shipping charges, carrier, cold-chain arrangements or package supply quantity. Readers should request those details for the actual prescription and destination. A plan’s duration is not proof of how much medication arrives in a particular shipment.

FDA advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. It also reports measurement and administration errors involving compounded medication, including some associated with hospitalization; those reports do not establish a Found-specific event rate. Clear instructions from the prescriber or pharmacist matter. This review cannot supply dosing calculations or substitute for shipment-specific advice.

Sources: [9] [10] [1]

Read the compounded prices as conditional billing terms

Found’s terms label compounded semaglutide and tirzepatide prices as including clinical care, medication and membership, with billing every four weeks. Applicable labs and branded GLP-1 medications are excluded. The table below preserves the published price sequence. Although the terms call these monthly prices, a 28-day cycle is not a calendar month; their 12-month duration corresponds to 48 weeks. These plan labels also do not establish shipment quantity.

The commercial pricing page says its lowest advertised prices require a 12-month plan paid upfront, whereas the terms describe prices billed every four weeks. Those statements need reconciliation before checkout: obtain the first charge, later charge schedule and actual service duration in writing. Do not assume the lowest figure is available month-to-month, or that the recurring-billing language eliminates upfront collection. Insurance-linked rates can also leave copays, coinsurance and deductibles payable separately.

New members choosing a one-month plan receive explicitly temporary discounts. Compounded semaglutide is $99 initially then $199 with insurance, or $179 then $289 cash-pay. Compounded tirzepatide is $149 initially then $289 with insurance, or $219 then $359 cash-pay. The introductory amount is not the renewal price. Separately, Found promotes annual-prepayment savings; that promotion does not resolve the documentation’s collection-schedule ambiguity.

Published compounded injectable plan rates per 28-day billing cycle; insurance-linked visit charges may be additional
Medication and payment route	1- / 3-month plan rate	6- / 12-month plan rate
Compounded semaglutide, insurance	$199 / $159	$129 / $99
Compounded semaglutide, cash-pay	$289 / $249	$219 / $169
Compounded tirzepatide, insurance	$289 / $239	$209 / $179
Compounded tirzepatide, cash-pay	$359 / $309	$289 / $239

Sources: [10] [12] [7]

Insurance, branded prescriptions and Medicare are separate issues

Found’s billing consent says compounded GLP-1 charges are the patient’s responsibility and must not be submitted to insurance. It also calls the subscription a noncovered service. Thus, “with insurance” does not mean the compounded drug itself is insured. Found’s free coverage checker can report medication coverage, prior-authorization requirements and available cost estimates, but it does not request treatment or issue a prescription. Coverage for clinical visits and coverage for medication require separate confirmation.

The branded plan includes prescription services and membership, not medication. Its 1/3/6/12-month rates are $89/$79/$69/$49 with insurance and $149/$139/$129/$99 cash-pay, billed every 28 days. The oral generics plan uses those same rates but includes prescription, medication and membership. Branded drugs may go through a chosen pharmacy using cash or insurance; eligible NovoCare or LillyDirect fulfillment is cash-pay only. The catalog lists Ozempic at $1,100 monthly, Mounjaro at approximately $1,100, and Wegovy and Zepbound starting at $650 monthly plus, without complete supply conditions.

Government-insurance terms conflict with a dedicated Medicare page. General offers exclude Medicare, Medicaid and similar plans from insurance rates; the Medicare page advertises care for ages 65–75 and conditional Bridge access. Found describes a July 2026–December 2027 program with a separate $50 monthly medication copay, outside ordinary Part D payment flow, not counting toward its deductible or out-of-pocket maximum; low-income subsidies do not apply. Eligibility is not guaranteed, and the documentation does not fully reconcile these routes.

Sources: [14] [11] [10] [12] [8]

Refund boundaries affect the enrollment decision

Found’s membership-refund policy first says cancellation within three days of the original purchase or before completing the first consultation qualifies for a full membership refund. Its next sentence makes the relationship between those milestones ambiguous. Obtain clarification rather than assuming the broader interpretation. Medical disqualification from every treatment option can qualify for a membership refund, but being unable to receive a preferred GLP-1 does not suffice if other Found treatments remain available.

Medication and lab kits become nonreturnable and nonrefundable once dispensed or shipped, even unused. Renewal payments are nonrefundable, and Found recommends canceling or pausing at least 48 hours before the scheduled renewal. Cancellation therefore should not be treated as a refund entitlement. The consulted documentation does not settle unused-prepayment refunds or fully explain cancellation mechanics. Any stated refund-processing period should not be understood as a guaranteed bank-posting date.

There are additional billing responsibilities beyond subscription renewal. Missing a scheduled consultation or canceling with less than 24 hours’ notice carries a $30 fee. Post-claim invoices are due within 15 days, after which Found can charge the card on file; failed payment leaves another 30 days to resolve the balance before subscription termination. These terms make a written explanation of likely visit charges and account cancellation especially useful before entering a longer plan.

Sources: [10] [14]

Questions & answers

Does Found guarantee a GLP-1 prescription?

No. Found describes assessment and clinical review before prescribing, with medication offered only when appropriate. Its refund policy also distinguishes rejection for a preferred medication from disqualification from all available treatments. Someone seeking only a particular product should clarify that distinction before purchasing membership.

Sources: [9] [6] [10]

Are the lowest advertised compounded prices cash-pay prices?

Not consistently across the documentation. The main terms place $99 semaglutide and $179 tirzepatide under the longest insurance-linked plans. The Medicare page describes those starting figures as cash-pay with membership separate. Request a personalized itemization rather than combining those descriptions into one confirmed offer.

Sources: [10] [8]

Why do Found’s branded-drug prices differ between pages?

The consulted documentation does not resolve that question. Catalog entries put Wegovy and Zepbound at $650 monthly plus, while compounded-drug comparison tables show $149–$349 and $299–$449 respectively, subject to cash-pay and multimonth conditions. Confirm product presentation, pharmacy channel, eligibility and membership charges before treating either figure as your price.

Sources: [12] [9] [5]

What do Found’s branded-plan checkout discounts cover?

Found advertises $100 off the initial cash-pay membership checkout supporting branded prescriptions, including Zepbound vials, Wegovy pens and Wegovy pills, or $50 off when Found is in-network with insurance. These are initial-checkout offers, limited to once per account and subject to change. Med Kit plans are excluded; medication should not be assumed included.

Sources: [7] [10]

Can I check the dispensing pharmacy before treatment?

Ask Found to identify the pharmacy for the proposed preparation, its contact information and the supporting testing records. The consulted pages describe 503A partnerships and third-party testing but do not supply pharmacy names or certificates. For branded prescriptions, Found documents a chosen-pharmacy route and conditional cash-pay manufacturer channels.

Sources: [9] [10]

What should I clarify about Medicare before enrolling?

Ask whether the dedicated Medicare pathway applies, which product and presentation qualify, and what membership costs separately. Found lists Wegovy injections and tablets, Zepbound KwikPen and Foundayo in its Bridge description, while warning eligibility is conditional. Its general government-insurance exclusion remains a separate term requiring reconciliation, not an assurance of coverage.

Sources: [8] [10]

Our assessment

Found documents a substantial online weight-care offering: multiple medication pathways, clinical assessment, differentiated visit formats, monthly follow-up and app-based support. That service detail is useful, but it does not establish provider-specific effectiveness or independently verify compounded-product quality. The most consequential unresolved issues are identifiable pharmacy testing records, location-specific availability, upfront versus recurring collection, inconsistent branded-drug prices and Medicare terms. A useful next step is a written, prescription-specific explanation of the product, pharmacy, care schedule, initial payment, renewals and refund boundaries. Found’s breadth is documented; the fit and full financial terms still require individual confirmation.

Visit Found’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Found Review: What Its GLP-1 Program Documents—and What It Does Not Prove

At a glance

01Start with what Found’s documents can establish

02The medication menu contains different evidence questions

03Clinical research does not certify the service

04Assessment, refills and support depend on the payment route

05Pharmacy assurances need identifiable supporting records

06Read the compounded prices as conditional billing terms

07Insurance, branded prescriptions and Medicare are separate issues

08Refund boundaries affect the enrollment decision